SMAD4 and colorectal carcinoma: Further support to the data discussed in the previous paragraph, about BET proteins being attractive targets in CRC, comes from the recent work from the Shim group, which used a different strategy—i.e., a synthetic lethality drug screening with a library of small-molecule inhibitors targeting the human epigenetic machinery—to uncover BET inhibitors (BET-i) as being synthetic lethal for CRC cells defective for SMAD4 [161].